Dosimetric evaluation to the Lung
| LungVGy(%) | p-level | ||||
|---|---|---|---|---|---|
| n | mean ± SD | min–max | median (IQR) | ||
| UHF | 40 | 8.1 ± 4.1 | 0.2–15.5 | 7.95 (5.5–11.1) | Z = 2.59 |
| HF | 40 | 11.8 ± 5.6 | 1.6–24.5 | 10.25 (7.5–16.2) | |
Tumor characteristics
| Variable | n | UHF | HF | p-level |
|---|---|---|---|---|
| Tumor stage | ||||
| 1b | 7 | 2 (5.26) | 5 (12.5) | p = 0.185 |
| 1c | 37 | 18 (47.37) | 19 (47.5) | |
| 1mi | 3 | 0 | 3 (7.5) | |
| 2 | 31 | 18 (47.37) | 13 (32.5) | |
| all | 78 | 38 | 40 | |
| Tumor size | ||||
| mean ± SD | 20.3 ± 8.2 | 16.3 ± 7.9 | t = 2.13 | |
| min-max | 7–45 | 1–35 | ||
| median (IQR) | 19 (15–22) | 15 (11.5–23) | ||
| Lymph nodes | ||||
| N0 | 73 | 36 (94.74) | 37 (92.5) | X2 = 0.0035 |
| N1 | 5 | 2 (5.26) | 3 (7.5) | |
| Grade | ||||
| G1 | 10 | 3 (8.11) | 7 (17.5) | X2 = 191 |
| G2 | 51 | 27 (72.97) | 24 (60) | |
| G3 | 16 | 7 (18.92) | 9 (22.5) | |
| Lymphovascular invasion | ||||
| LV 0 | 42 | 21 (61.76) | 21 (56.76) | X2 = 0.18 |
| LV 1 | 29 | 13 (38.24) | 16 (43.24) | |
| Histopathological type | ||||
| NST | 56 | 29 (72.5) | 27 (67.5) | p = 0.23 |
| lobular | 11 | 6 (15) | 5 (12.5) | |
| mixed | 4 | 2 (5) | 2 (5) | |
| other | 7 | 1 (2.5) | 6 (15) | |
| Tis | 2 | 2 (5) | 0 | |
| ER/HER2 | ||||
| ER+ HER2+ | 8 | 4 (10.53) | 4 (10) | p = 0.344 |
| ER+ HER2- | 59 | 31 (81.58) | 28 (70) | |
| ER-HER2+ | 3 | 0 | 3 (7.5) | |
| ER-HER2- | 8 | 3 (7.89) | 5 (12.5) | |
Patients’ characteristics
| Variable | n | UHF | HF | p-level |
|---|---|---|---|---|
| Age (years) | mean ± SD | min-max | ||
| UHF | 40 | 60.8 ± 7.1 | 50–75 | t = 0.37 |
| HF | 40 | 61.35± 6.2 | 50–74 | p = 0.712 |
| Side | ||||
| Right | 38 | 22 (55) | 16 (40) | X2 = 1.8 |
| Center | 42 | 18 (45) | 24 (60) | p = 0.18 |
| Chemotherapy | ||||
| No | 50 | 24 (63.2) | 26 (65) | X2 = 0.029 |
| Yes | 28 | 14 (36.8) | 14 (35) | p = 0.865 |
| Hormonal therapy | ||||
| No | 8 | 2 (5.3) | 6 (15) | X2 = 1.09 |
| Yes | 70 | 36 (94.7) | 34 (85) | p = 0.297 |
| Target therapy | ||||
| No | 65 | 32 (84.2) | 33 (82.5) | X2 = 0.041 |
| Yes | 13 | 6 (15.8) | 7 (17.5) | p = 0.839 |
| Breast size | ||||
| < 1300 cm3 | 68 | 36 (90) | 32 (80) | X2 = 1.57 |
| > 1300 cm3 | 12 | 4 (10) | 8 (20) | p = 0.21 |
Dosimetric evaluation of PTV
| PTV95% | p-level | |||
|---|---|---|---|---|
| n | mean ± SD | min–max | ||
| UHF | 40 | 99.3 ± 0.6 | 97.4 – 100 | t = 4.9 |
| HF | 40 | 98.3 ± 1.2 | 95.2 – 99.9 | |
Dosimetric evaluation of dose to the Heart
| HeartV(%)) | p-level | ||||
|---|---|---|---|---|---|
| n | mean ± SD | min–max | median (IQR) | ||
| UHF | 19 | 7.7 ±4.0 | 0–16.3 | 7.5 (5.7–9.5) | Z = 3.3 |
| HF | 24 | 3.7 ± 2.9 | 0.03–10.0 | 3.1 (1.4–5.0) | |